News

Filter

Current filters:

XareltoResearch

1 to 9 of 30 results

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

02-09-2014

German pharma and chemical major Bayer has released results from the X-VeRT* study, demonstrating that…

BayerCardio-vascularPharmaceuticalResearchXarelto

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

01-04-2014

German drug major Bayer presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

“Breakthrough Therapy” status for Portola’s andexanet alfa

25-11-2013

USA-based Portola Pharmaceuticals has been granted “Breakthrough Therapy” designation by the US Food…

andexanet alfaBayerBristol-Myers SquibbCardio-vascularEliquisNorth AmericaPharmaceuticalPortola PharmaceuticalsRegulationResearchXarelto

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

19-11-2013

Presented for the first time at the American Heart Association’s (AHA) Scientific Sessions, results…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPharmaceuticalPradaxaResearchXarelto

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

22-09-2013

Data from the Phase III EINSTEIN clinical trial program published Friday in the Thrombosis Journal underline…

BayerCardio-vascularPharmaceuticalResearchXarelto

1 to 9 of 30 results

COMPANY SPOTLIGHT

Menarini

Back to top